Although modified-release (MR) formulations offer many therapeutic benefits, there are many challenges to overcome when trying to develop this type of formulation.
Quotient Sciences has the expertise to help develop your modified-release form, with the insight to support even the most challenging modified-release programs.
Rising to the challenge of MR formulations
The popularity of modified-release (MR) dosage forms continues to rise due to the many therapeutic benefits that they offer for both drug developers and patients. Oral MR formulations are designed to control the rate and/or location of drug release in the gastrointestinal (GI) tract.
In contrast to immediate-release (IR) formulations, MR dosage forms can offer:
- maintenance of drug plasma concentrations over a prolonged period to reduce dosing frequency
- attenuation of drug peak-to-trough ratios to reduce peak-related adverse events (AEs) and improve efficacy
- drug delivery to targeted regions of the GI tract for localized treatment.
Alternative Strategies for Development of Modified Release Dosage Forms
Read MoreExtensive modified-release formulation expertise brought to every program.
Over the past three decades, we have supported hundreds of modified-release formulations across a wide variety of therapeutic areas. Our extensive background in formulation development and our agile approach to clinical trial materials manufacturing and commercial drug product manufacturing makes us the ideal partner to help in the development of your next modified-release formulation.
What are examples of different modified-release dosage forms?
Explore some of the types of modified release and sustained release dosage forms that we can help you address.
Have a specific question about a modified release or sustained release dosage form?
Gastro-retention
dosage forms
Includes swellable tablets (monolithic, bilayer, trilayer) that keep the formulation in the stomach for an extended period to maximize the duration of absorption or therapeutic activity
Gastro-resistant
dosage forms
Enteric-coated tablets or capsules that prevent release of the drug in the stomach and/or upper gastrointestinal (GI) tract.
Extended release
dosage forms
Matrix tablets, coated tablets, or multiparticulates that allow for extended or sustained release.
With extended-release dosage forms, we can adjust the in-vivo release profile of the drug, enabling once-daily dosing.
Pulsatile release
dosage forms
Pulsatile release dosage forms are beneficial for drugs where time-dependent dosing is required or those that undergo first-pass metabolism.
Biphasic release
dosage forms
Biphasic release dosage forms can give a rapid therapeutic effect from an immediate-release layer and extended dosing from a sustained-release layer, eliminating the need for repeat dosing.
Meet our modified release experts
We help transform your molecules into the medicines of the future. Our partnership is focused on a single goal: Delivering new treatments to those in need. Fast.
Meet some of the team members you’ll collaborate with on your project.
Dr. Andrew Lewis
Chief Scientific Officer
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...
About Andrew
Dr. Asma Patel
VP, Integrated Development Services
Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...
About Asma
Dr. Vanessa Zann
Vice President, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA
Dr. Vanessa Zann, Vice President, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA, has over t...
About Vanessa
John McDermott
Vice President, Scientific Consulting
John McDermott is Vice President of Scientific Consulting at Quotient Sciences. John leads Quotient Sciences' global drug developm...
About John
